Loading…
Zhejiang Huahai Pharmaceutical Co., Ltd., a drug manufacturer in China, violated Current Good Manufacturing Practice (CGMP) regulations during an FDA inspection conducted January 16-24, 2025. The company failed to adequately clean, maintain, and sanitize non-dedicated manufacturing equipment, with FDA investigators observing residue on surfaces of equipment documented as having undergone product changeover cleaning, including ducts and associated valves. This violation was particularly significant because the company had been cited for similar issues involving unknown residue in equipment during a previous FDA inspection. The manufacturing failures rendered the company's drug products adulterated and non-compliant with federal regulations.